Suppr超能文献

具有 9p24/JAK2 重排的造血系统肿瘤:一项多中心研究。

Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.

机构信息

Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

Department of Pathology, University of Chicago, Chicago, IL, USA.

出版信息

Mod Pathol. 2019 Apr;32(4):490-498. doi: 10.1038/s41379-018-0165-9. Epub 2018 Nov 6.

Abstract

The purpose of this study is to examine hematopoietic neoplasms with 9p24/JAK2 rearrangement including neoplasms associated with t(8;9)(p22;p24)/PCM1-JAK2 fusion neoplasm as well as cases with translocations involving 9p24/JAK2 and other partner genes. From seven large medical centers, we identified ten patients with t(8;9)(p22;p24) /PCM1-JAK2 and 3 with t(9p24;v)/JAK2 at diagnosis. Majority of the cases showed myeloproliferative neoplasm (MPN) associated features (n = 7) characterized by variable degrees of eosinophilia, myelofibrosis, frequent proliferations of early erythroblasts in bone marrow and extramedullary sites, and infrequent/absent somatic mutations. Other less common presentations included myelodysplastic syndromes (MDS) or MDS/MPN (one each). Four patients presented with B-lymphoblastic leukemia (B-ALL), and of them, two patients with t(8;9)(p22;p24.1) were proven to be B-lymphoblastic crisis of MPN; and the other two cases with t(9p24;v) both were de novo B-ALL, BCR-ABL1-like (Ph-like). We show that the hematopoietic neoplasms with 9p24/JAK2 rearrangement are extremely rare, and most of them are associated with t(8;9)(p22;p24)/PCM1-JAK2, a recent provisional World Health Organization entity under "myeloid/lymphoid neoplasm with a specific gene rearrangement". Cases of t(8;9)(p22;p24)/PCM1-JAK2, though heterogeneous, do exhibit some common clinicopathological characteristic features. Cases with t(9p24;v)/JAK2 are extremely rare; while such cases with a MPN presentation may resemble t(8;9)(p22;p24.1)/PCM1-JAK2, B-ALL cases presenting de novo B-ALL might belong to Ph-like B-ALL.

摘要

本研究旨在探讨 9p24/JAK2 重排的造血肿瘤,包括与 t(8;9)(p22;p24)/PCM1-JAK2 融合肿瘤相关的肿瘤以及涉及 9p24/JAK2 和其他伙伴基因的易位病例。我们从七个大型医疗中心中确定了 10 例 t(8;9)(p22;p24)/PCM1-JAK2 和 3 例 t(9p24;v)/JAK2 初诊病例。大多数病例表现出骨髓增殖性肿瘤(MPN)相关特征(n=7),特征为不同程度的嗜酸性粒细胞增多、骨髓纤维化、骨髓和骨髓外部位早期红细胞增殖频繁、体细胞突变罕见/缺失。其他不太常见的表现包括骨髓增生异常综合征(MDS)或 MDS/MPN(各 1 例)。4 例表现为 B 淋巴细胞白血病(B-ALL),其中 2 例 t(8;9)(p22;p24.1)患者被证实为 MPN 的 B 淋巴细胞白血病危象;另外 2 例 t(9p24;v)患者均为初发 B-ALL,BCR-ABL1 样(Ph 样)。我们表明,9p24/JAK2 重排的造血肿瘤极为罕见,大多数与 t(8;9)(p22;p24)/PCM1-JAK2 相关,后者是最近在“具有特定基因重排的髓系/淋巴系肿瘤”下提出的暂定的世界卫生组织实体。尽管 t(8;9)(p22;p24)/PCM1-JAK2 病例存在异质性,但确实表现出一些共同的临床病理特征。t(9p24;v)/JAK2 病例极为罕见;而具有 MPN 表现的病例可能与 t(8;9)(p22;p24.1)/PCM1-JAK2 相似,初发 B-ALL 病例可能属于 Ph 样 B-ALL。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验